A case of an acromegalic patient resistant to the recommended maximum GH receptor antagonist dosage

作者：Dimopoulou C^*; Sievers C; Bidlingmaier M; Stalla G K

来源：Hippokratia, 2012, 16(1): 80-82.

• acromegaly
• GH receptor antagonist
• resistance

Background: The competitive GH receptor antagonist pegvisomant is reported to normalise IGF-1 levels in up to 97 % of acromegalic patients at a maximum dosage of 40 mg/d.
Description of Case: We present an acromegalic patient resistant to the recommended maximum GH receptor antagonist dosage. The 60-year-old male patient presenting with typical clinical signs of acromegaly has underwent multiple transsphenoidal surgeries and pituitary irradiation, while currently available pharmacological therapies for acromegaly have been exhausted.
Results: Biochemical control of the disease could only be achieved until uptitration of pegvisomant to 60 mg/d which was tolerated well.
Conclusions: The current treatment algorithm for acromegaly should be modified to treat cases of persistent and uncontrolled disease. Hippokratia. 2012; 16 (1): 80-82

• 出版日期2012-3